[go: up one dir, main page]

WO2002057791A3 - Diagnostic and therapeutic compositions and methods related to grp 38 - Google Patents

Diagnostic and therapeutic compositions and methods related to grp 38 Download PDF

Info

Publication number
WO2002057791A3
WO2002057791A3 PCT/US2001/045219 US0145219W WO02057791A3 WO 2002057791 A3 WO2002057791 A3 WO 2002057791A3 US 0145219 W US0145219 W US 0145219W WO 02057791 A3 WO02057791 A3 WO 02057791A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
compositions
grp
diagnostic
adenocarcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/045219
Other languages
French (fr)
Other versions
WO2002057791A2 (en
Inventor
Joseph P Brown
Glenna C Burmer
Christine L Roush
Bruce G Kulander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeSpan BioSciences Inc
Original Assignee
LifeSpan BioSciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LifeSpan BioSciences Inc filed Critical LifeSpan BioSciences Inc
Priority to AU2002245051A priority Critical patent/AU2002245051A1/en
Publication of WO2002057791A2 publication Critical patent/WO2002057791A2/en
Priority to US10/206,677 priority patent/US20030186336A1/en
Publication of WO2002057791A3 publication Critical patent/WO2002057791A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention comprises systems, methods, compositions and the like, such as diagnostics, medicaments and therapeutics, relating to GPR 38 and Alzheimer's disease and Parkinson's disease, inflammatory bowel diseases including ulcerative colitis and Crohn's disease, Hodgkin's disease, glioblastoma and carcinomas including breast, colon, lung (small cell and adenocarcinoma) pancreatic (small cell and adenocarcinoma), ovarian, and prostate. Such diagnostics and therapeutics include peptide, protein, antibody and nucleic acid based compositions, including agonists, antagonists, probes, antisense and gene therapy compositions.
PCT/US2001/045219 2000-11-29 2001-11-29 Diagnostic and therapeutic compositions and methods related to grp 38 Ceased WO2002057791A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002245051A AU2002245051A1 (en) 2000-11-29 2001-11-29 Diagnostic and therapeutic compositions and methods related to grp 38
US10/206,677 US20030186336A1 (en) 2001-11-29 2002-07-26 Diagnostic and therapeutic compositions and methods related to GPCR 38, a G protein-coupled receptor (GPCR)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25025100P 2000-11-29 2000-11-29
US60/250,251 2000-11-29
US25045200P 2000-11-30 2000-11-30
US60/250,452 2000-11-30

Publications (2)

Publication Number Publication Date
WO2002057791A2 WO2002057791A2 (en) 2002-07-25
WO2002057791A3 true WO2002057791A3 (en) 2003-03-27

Family

ID=26940725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045219 Ceased WO2002057791A2 (en) 2000-11-29 2001-11-29 Diagnostic and therapeutic compositions and methods related to grp 38

Country Status (2)

Country Link
AU (1) AU2002245051A1 (en)
WO (1) WO2002057791A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003288251A1 (en) * 2002-12-23 2004-07-14 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor 38 (gpr38)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712253A (en) * 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
US5972939A (en) * 1997-10-28 1999-10-26 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene derivatives useful as antagonists of the motilin receptor
EP1006122A1 (en) * 1997-08-15 2000-06-07 Chugai Seiyaku Kabushiki Kaisha Phenethylamine derivatives
WO2001064836A2 (en) * 2000-03-01 2001-09-07 Smithkline Beecham Corporation Cloning of a gpr38 variant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712253A (en) * 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
EP1006122A1 (en) * 1997-08-15 2000-06-07 Chugai Seiyaku Kabushiki Kaisha Phenethylamine derivatives
US5972939A (en) * 1997-10-28 1999-10-26 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene derivatives useful as antagonists of the motilin receptor
WO2001064836A2 (en) * 2000-03-01 2001-09-07 Smithkline Beecham Corporation Cloning of a gpr38 variant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEIGHNER S D ET AL: "RECEPTOR FOR MOTILIN IDENTIFIED IN THE HUMAN GASTROINTESTINAL SYSTEM", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 284, no. 5423, 25 June 1999 (1999-06-25), pages 2184 - 2188, XP001088406, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
AU2002245051A1 (en) 2002-07-30
WO2002057791A2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
Kakolyris et al. Expression and subcellular localization of human AP endonuclease 1 (HAP1/Ref‐1) protein: A basis for its role in human disease
Aggarwal et al. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity
Aouida et al. The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5
Shen et al. Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA)
WO1999038972A9 (en) Human genes and gene expression products ii
WO2002014500A3 (en) Human genes and gene expression products
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
WO1999058675A3 (en) Human genes and gene expression products v
WO2003097803A3 (en) Cancer-linked gene as target for chemotherapy
WO2001066753A3 (en) Human genes and gene expression products
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
ZA200508390B (en) Compositions and methods for the therapy of inflammatory bowel disease
WO2017011769A2 (en) Il-17f-specific capture agents, compositions, and methods of using and making
WO2001068705A3 (en) Il-17 receptor like molecules and uses thereof
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
WO2001064877A3 (en) Human schizophrenia gene
Read et al. Combined Vorinostat and Chloroquine Inhibit Sodium–Iodide Symporter Endocytosis and Enhance Radionuclide Uptake In Vivo
WO2001012819A3 (en) Protein phosphatases and diagnosis and treatment of phosphatase-related disorders
Benloucif et al. Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies
CA2446327A1 (en) A polypeptide and dna thereof useful as a neovascular marker
WO2002057791A3 (en) Diagnostic and therapeutic compositions and methods related to grp 38
Zhang et al. Cysteine-accessibility analysis of transmembrane domains 11–13 of human concentrative nucleoside transporter 3
PL374550A1 (en) Il-17 like molecules and uses thereof
Fang et al. GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP